292 related articles for article (PubMed ID: 8724143)
1. Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties.
Lapierre F; Holme K; Lam L; Tressler RJ; Storm N; Wee J; Stack RJ; Castellot J; Tyrrell DJ
Glycobiology; 1996 Apr; 6(3):355-66. PubMed ID: 8724143
[TBL] [Abstract][Full Text] [Related]
2. Structural requirements for inhibition of melanoma lung colonization by heparanase inhibiting species of heparin.
Bitan M; Mohsen M; Levi E; Wygoda MR; Miao HQ; Lider O; Svahn CM; Ekre HP; Ishai-Michaeli R; Bar-Shavit R
Isr J Med Sci; 1995; 31(2-3):106-18. PubMed ID: 7744578
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of tumor metastasis by heparanase inhibiting species of heparin.
Vlodavsky I; Mohsen M; Lider O; Svahn CM; Ekre HP; Vigoda M; Ishai-Michaeli R; Peretz T
Invasion Metastasis; 1994-1995; 14(1-6):290-302. PubMed ID: 7657522
[TBL] [Abstract][Full Text] [Related]
4. Chemically modified heparins as inhibitors of heparan sulfate specific endo-beta-glucuronidase (heparanase) of metastatic melanoma cells.
Irimura T; Nakajima M; Nicolson GL
Biochemistry; 1986 Sep; 25(18):5322-8. PubMed ID: 3768351
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides.
Miao HQ; Elkin M; Aingorn E; Ishai-Michaeli R; Stein CA; Vlodavsky I
Int J Cancer; 1999 Oct; 83(3):424-31. PubMed ID: 10495437
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of B16-BL6 melanoma lung colonies by semisynthetic sulfaminoheparosan sulfates from E. coli K5 polysaccharide.
Poggi A; Rossi C; Casella N; Bruno C; Sturiale L; Dossi C; Naggi A
Semin Thromb Hemost; 2002 Aug; 28(4):383-92. PubMed ID: 12244486
[TBL] [Abstract][Full Text] [Related]
7. Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate.
Vlodavsky I; Ilan N; Naggi A; Casu B
Curr Pharm Des; 2007; 13(20):2057-73. PubMed ID: 17627539
[TBL] [Abstract][Full Text] [Related]
8. Heparanases and tumor metastasis.
Nakajima M; Irimura T; Nicolson GL
J Cell Biochem; 1988 Feb; 36(2):157-67. PubMed ID: 3281960
[TBL] [Abstract][Full Text] [Related]
9. Human platelet heparanase: purification, characterization and catalytic activity.
Freeman C; Parish CR
Biochem J; 1998 Mar; 330 ( Pt 3)(Pt 3):1341-50. PubMed ID: 9494105
[TBL] [Abstract][Full Text] [Related]
10. Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis.
Edovitsky E; Elkin M; Zcharia E; Peretz T; Vlodavsky I
J Natl Cancer Inst; 2004 Aug; 96(16):1219-30. PubMed ID: 15316057
[TBL] [Abstract][Full Text] [Related]
11. A rapid quantitative assay for the detection of mammalian heparanase activity.
Freeman C; Parish CR
Biochem J; 1997 Jul; 325 ( Pt 1)(Pt 1):229-37. PubMed ID: 9224651
[TBL] [Abstract][Full Text] [Related]
12. Murine macrophage heparanase: inhibition and comparison with metastatic tumor cells.
Savion N; Disatnik MH; Nevo Z
J Cell Physiol; 1987 Jan; 130(1):77-84. PubMed ID: 3805131
[TBL] [Abstract][Full Text] [Related]
13. P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins.
Hostettler N; Naggi A; Torri G; Ishai-Michaeli R; Casu B; Vlodavsky I; Borsig L
FASEB J; 2007 Nov; 21(13):3562-72. PubMed ID: 17557930
[TBL] [Abstract][Full Text] [Related]
14. Structural features of heparanase-inhibiting non-anticoagulant heparin derivative Roneparstat.
Alekseeva A; Mazzini G; Giannini G; Naggi A
Carbohydr Polym; 2017 Jan; 156():470-480. PubMed ID: 27842848
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of experimental metastasis and extracellular matrix degradation by butanol extracts from B16-F1 murine melanoma.
Keren Z; Leland F; Nakajima M; LeGrue SJ
Cancer Res; 1989 Jan; 49(2):295-300. PubMed ID: 2910449
[TBL] [Abstract][Full Text] [Related]
16. Structure and biological activity of heparinoid.
Kumar N; Bentolila A; Domb AJ
Mini Rev Med Chem; 2005 May; 5(5):441-7. PubMed ID: 15892686
[TBL] [Abstract][Full Text] [Related]
17. Non-Anticoagulant Heparins as Heparanase Inhibitors.
Cassinelli G; Torri G; Naggi A
Adv Exp Med Biol; 2020; 1221():493-522. PubMed ID: 32274724
[TBL] [Abstract][Full Text] [Related]
18. Identification and characterization of heparin/heparan sulfate binding domains of the endoglycosidase heparanase.
Levy-Adam F; Abboud-Jarrous G; Guerrini M; Beccati D; Vlodavsky I; Ilan N
J Biol Chem; 2005 May; 280(21):20457-66. PubMed ID: 15760902
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin species.
Bar-Ner M; Eldor A; Wasserman L; Matzner Y; Cohen IR; Fuks Z; Vlodavsky I
Blood; 1987 Aug; 70(2):551-7. PubMed ID: 2955820
[TBL] [Abstract][Full Text] [Related]
20. Cancer cell heparanase activity associated with invasion and metastasis.
Nicolson GL; Nakajima M; Wakabayashi H; Boyd DD; Diaz D; Irimura T
Adv Enzyme Regul; 1998; 38():19-32. PubMed ID: 9762344
[No Abstract] [Full Text] [Related]
[Next] [New Search]